Loading
CD52 is a small protein on nearly all lymphocytes and the target of alemtuzumab, a profoundly immunosuppressive antibody once used in CLL and now mostly in transplant conditioning, T-cell leukaemia and multiple sclerosis. This dossier gathers the 2 products (1 approved), 2 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
GPI-anchored 12-amino-acid glycopeptide of unknown function on lymphocytes, monocytes and the male reproductive tract; extremely high surface density makes it an efficient complement-fixing target.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Chronic lymphocytic leukaemia | 100% | Surface CD52 on essentially all B and T lymphocytes (Campath label); CLL cells uniformly CD52-positive | IHC survey of 294 haematologic neoplasms: vast majority of CLL/SLL positive (Rodig 2006, doi:10.1158/1078-0432.CCR-06-1275) | FDA |
| Peripheral T-cell lymphomas | 92.3% | Flow cytometry, surface CD52 in PTCL-NOS (12 of 13); ATLL 94.1%, CTCL 87.5%, ALCL 50%, NK/T 25% | Small series; paraffin IHC found most PTCL-NOS negative (Rodig 2006), so test each case before alemtuzumab | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved | Phase 2 |
|---|---|---|
| Antibody 2 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 1/2 | Active | A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL) | - | ||
| 1/2 | Recruiting | Open-label Dose-finding and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"CD52" OR ABSTRACT:"CD52") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD52, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/cd52.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cd52.json. Licence CC BY-NC 4.0.